Charlotte Lemech

Senior Lecturer

Scientia Clinical Research (SCR) is the first publicly funded purpose built early phase clinical trials centre in UNSW.  We will conduct first-in-human and first-in-patient studies in cancer and across other disciplines, both for novel therapies as well as methods of disease diagnosis and detection.  As part of the Bright Alliance with Prince of Wales Hospital, the Royal Hospital for Women, Sydney Children's Hospital and UNSW, Scientia will provide a research hub and state of the art clinical care.

After completing my FRACP in medical oncology in the SESIAHS network, I worked for 4 years in London at an early phase clinical trials unit, Sarah Cannon Research UK, and completed a MD(res) at University College London.  For my MD(res), I researched biomarker development in endometrial cancer including circulating tumour cells and methylation studies.

I have experience in managing phase I-III clinical trials across a spectrum of tumour streams and molecular targets including immunotherapy, PI3K/Akt, RAF/MEK, FAK, FGFR and others.

  

publications

Journal articles
add
Berry S; Giraldo N; Nguyen P; Green B; Xu H; Ogurtsova A; Soni A; Succaria F; Wang D; Roberts C; Stein J; Engle E; Pardoll D; Anders R; Cottrell T; Taube JM; Tran B; Voskoboynik M; Kuo J; Bang YL; Chung HC; Ahn MJ; Kim SW; Perera A; Freeman D; Achour I; Faggioni R; Xiao F; Ferte C; Lemech C; Meric-Bernstam F; Werner T; Hodi S; Messersmith W; Lewis N; Talluto C; Dostalek M; Tao A; McWhirter S; Trujillo D; Luke J; Xu C; Bomarelli B; Qi J; Qin G; Yu H; Jenkins M; Lo KM; Halle JP; Lan Y; Taylor M; Vogelzang N; Cohn A; Stepan D; Shumaker R; Dutcus C; Guo M; Schmidt E; Rasco D; Brose M; Di Simone C; Jain S; Richards D; Encarnacion C; Vogelzeng N; Mier J; An J; Yang YY; Lee WH; Yang J; Kim JK; Kim HG; Paek SH; Lee JW; Woo J; Kim JB; Kwon H; Lim W; Paik NS; Kim YK; Moon BI; Janku F; Tan D; Martin-Liberal J; Takahashi S; Geva R; Gucalp A; Chen X; Subramanian K; Mataraza J; Wheler J; Bedard P, 2019, 'Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)', Journal for ImmunoTherapy of Cancer, vol. 7, http://dx.doi.org/10.1186/s40425-019-0519-y
2019
Coward J; Lemech C; Meniawy T; Dupont CD; Gonzalez AM; Lim M; Savitsky D; Carini M; Hu S; Shebanova O; Dow E; Ortuzar W; Buell JS; Stein RB; Youssoufian H, 2018, 'Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii417, http://dx.doi.org/10.1093/annonc/mdy288.041
2018
Goldstein D; Lemech C; Valle J, 2017, 'New molecular and immunotherapeutic approaches in biliary cancer', ESMO Open, vol. 2, http://dx.doi.org/10.1136/esmoopen-2016-000152
2017
Mateo J; Ganji G; Lemech C; Burris HA; Han SW; Swales K; Decordova S; DeYoung MP; Smith DA; Kalyana-Sundaram S; Wu J; Motwani M; Kumar R; Tolson JM; Rha SY; Chung HC; Eder JP; Sharma S; Bang YJ; Infante JR; Yan L; De Bono JS; Arkenau HT, 2017, 'A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors', Clinical Cancer Research, vol. 23, pp. 5981 - 5992, http://dx.doi.org/10.1158/1078-0432.CCR-17-0725
2017
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; De Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG, 2016, 'Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma', Blood, vol. 128, pp. 1821 - 1828, http://dx.doi.org/10.1182/blood-2016-07-726729
2016
Hughes A; Landers D; Arkenau HT; Shah S; Stephens R; Mahal A; Simmons M; Lemech C; Royle J, 2016, 'Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT', Advances in Therapy, vol. 33, pp. 1012 - 1024, http://dx.doi.org/10.1007/s12325-016-0335-4
2016
Lemech CR; Williams R; Thompson SR; McCaughan B; Chin M, 2016, 'Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report', BMC Research Notes, vol. 9, http://dx.doi.org/10.1186/s13104-016-2189-x
2016
Hughes A; Landers D; Arkenau HT; Shah S; Stephens R; Mahal A; Simmons M; Lemech C; Royle J, 2016, 'Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT (Adv Ther, (2016), 33, (1012-1024), 10.1007/s12325-016-0335-4)', Advances in Therapy, vol. 33, pp. 1677 - 1678, http://dx.doi.org/10.1007/s12325-016-0390-x
2016
Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT, 2016, 'Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, vol. 77, pp. 1275 - 1283, http://dx.doi.org/10.1007/s00280-016-3031-9
2016
Lemech CR; Ensell L; Paterson JC; Eminowicz G; Lowe H; Arora R; Arkenau HT; Widschwendter M; MacDonald N; Olaitan A; Mould T; Meyer T; Hartley J; Mitra A; Ledermann JA; McCormack M; Kristeleit RS, 2016, 'Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer', Oncology (Switzerland), vol. 91, pp. 48 - 54, http://dx.doi.org/10.1159/000445999
2016
Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M, 2016, 'A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 27, pp. 2268 - 2274, http://dx.doi.org/10.1093/annonc/mdw427
2016
Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT, 2015, 'Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer', Journal of Clinical Pharmacology, vol. 55, pp. 1378 - 1385, http://dx.doi.org/10.1002/jcph.560
2015
Lemech C; Dua D; Newmark J; Saggese M; Simmons E; Spiliopoulou P; Arkenau HT, 2015, 'Patients' perceptions of research biopsies in phase i oncology trials', Oncology (Switzerland), vol. 88, pp. 95 - 102, http://dx.doi.org/10.1159/000368161
2015
Hillman RJ; Garland SM; Gunathilake MPW; Stevens M; Kumaradevan N; Lemech C; Ward RL; Meagher A; McHugh L; Jin F; Carroll S; Goldstein D; Grulich AE; Tabrizi SN, 2014, 'Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers', International Journal of Cancer, vol. 135, pp. 996 - 1001, http://dx.doi.org/10.1002/ijc.28730
2014
Plesner T; Arkenau H-T; Lokhorst HM; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Ahmadi T; Yeh H; Guckert ME; Feng H; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma', BLOOD, vol. 124, http://dx.doi.org/10.1182/blood.V124.21.84.84
2014
Lemech CR; Arkenau HT, 2013, 'The future is here: Tumour profiling in day-to-day clinical practice', Drug Discovery Today, vol. 18, pp. 689 - 691, http://dx.doi.org/10.1016/j.drudis.2013.06.006
2013
Baird RD; Cresti N; Beddowes E; Saggese M; Flynn M; Corbacho JG; Gao F; Lemech C; Donaldson K; Posner J; Kawabata I; Forster M; Arkenau HT; Plummer R; Jodrell D; Spicer J, 2013, 'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer', CANCER RESEARCH, vol. 73, http://dx.doi.org/10.1158/0008-5472.SABCS13-P4-12-24
2013
Lemech CR; Arkenau HT, 2013, 'Rationally Designed Drug Development beyond BRAF Inhibition in Metastatic Cutaneous Melanoma', World Journal of Cancer Research
2013
Jones A; Teschendorff AE; Li Q; Hayward JD; Kannan A; Mould T; West J; Zikan M; Cibula D; Fiegl H; Lee SH; Wik E; Hadwin R; Arora R; Lemech C; Turunen H; Pakarinen P; Jacobs IJ; Salvesen HB; Bagchi MK; Bagchi IC; Widschwendter M, 2013, 'Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development', PLoS Medicine, vol. 10, http://dx.doi.org/10.1371/journal.pmed.1001551
2013
Saggese M; Dua D; Simmons E; Lemech C; Arkenau HT, 2013, 'Research biopsies in the context of early phase oncology studies: Clinical and ethical considerations', Oncology Reviews, vol. 7, pp. 34 - 37, http://dx.doi.org/10.4081/oncol.2013.e5
2013
Lemech C; Infante J; Arkenau HT, 2013, 'Combination molecularly targeted drug therapy in metastatic melanoma: Progress to date', Drugs, vol. 73, pp. 767 - 777, http://dx.doi.org/10.1007/s40265-013-0049-8
2013
Arkenau HT; Saggese M; Lemech C, 2012, 'Dabrafenib mesylate: Serine/threonine-protein kinase B-raf inhibitor oncolytic', Drugs of the Future, vol. 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872
2012
Lemech C; Infante J; Arkenau HT, 2012, 'The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: Rationale and latest evidence', Therapeutic Advances in Medical Oncology, vol. 4, pp. 61 - 73, http://dx.doi.org/10.1177/1758834011432949
2012
Arkenau H-T; Saggese M; Lemech C, 2012, 'DABRAFENIB MESYLATE Serine/Threonine-Protein Kinase B-raf Inhibitor, Oncolytic', DRUGS OF THE FUTURE, vol. 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872
2012
Lemech C; Arkenau HT, 2012, 'Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities', Clinical Medicine Insights: Oncology, vol. 6, pp. 53 - 66, http://dx.doi.org/10.4137/CMO.S5855
2012
Arkenau HT; Saggese M; Lemech C, 2012, 'Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?', World Journal of Gastroenterology, vol. 18, pp. 6376 - 6378, http://dx.doi.org/10.3748/wjg.v18.i44.6376
2012
Anglesio M; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin P; House CM; Chakravarty P; Gorringe K; Campbell I; George J, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, vol. 17, pp. 2538 - 2548, http://dx.doi.org/10.1158/1078-0432.CCR-10-3314
2011
Lemech C; Arkenau HT, 2011, 'Biomarkers in advanced colorectal cancer: Challenges in translating clinical research into practice', Cancers, vol. 3, pp. 1844 - 1860, http://dx.doi.org/10.3390/cancers3021844
2011
Conference Papers
add
Kuo J; Bampton D; Lemech CR; Brown MP; Stanley A; Chojnowski G; Hammond E; Dredge K; Goldstein D, 2018, 'Preliminary results from a Phase Ib study of pixatimod (PG545) in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, Dublin, IRELAND, pp. E18 - E19, presented at 30th EORTC-NCI-AACR Symposium, Dublin, IRELAND, 13 November 2018 - 16 November 2018
2018
Plesner T; Arkenau H-T; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; Yeh H; Ahmadi T; Lokhorst HM; Richardson PG, 2015, 'Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)', in BLOOD, AMER SOC HEMATOLOGY, Orlando, FL, presented at 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.507.507
2015
Arkenau H-T; Saggese M; Hollebecque A; Mathewson A; Lemech CR; Landers D; Frewer P; Kilgour E; Brooks N, 2014, 'A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Chicago, IL, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2620
2014
Plesner T; Arkenau H-T; Lokhorst HM; Gimsing P; Krejcik J; Lemech CR; Minnema M; Lassen UN; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Chicago, IL, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.8533
2014
Plesner T; Arkenau HT; Lokhorst HM; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, Milan, ITALY, pp. 104 - 104, presented at 19th Congress of the European-Hematology-Association, Milan, ITALY, 12 June 2014 - 15 June 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830900251&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Lemech CR; Ensell L; Paterson J; Eminowicz G; Lowe H; Griffin N; Arora R; Arkenau H-T; Widschwendter M; MacDonald N; Olaitan A; Mould T; Meyer T; Hartley JA; Mitra A; Ledermann JA; McCormack M; Kristeleit RS, 2014, 'Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Chicago, IL, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5600
2014
Arkenau H-T; Mateo J; Lemech CR; Infante JR; Burris HA; Bang Y-J; Eder JP; Herbst RS; Sharma S; Chung HC; Decordova S; Swales KE; Garrett MD; Loftiss JI; Durante M; Russo MW; Suttle BB; Motwani M; Kumar R; De Bono JS, 2014, 'A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Chicago, IL, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2514
2014
Lemech CR; Newmark J; Arkenau H-T, 2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice: A multi-institutional multinational survey', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 31 May 2013 - 04 June 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419604404&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2013
Plesner T; Arkenau T; Lokhorst H; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Cakana A; Brun NC; Basse L; Palumbo A; Richardson PG, 2013, 'Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma', in BLOOD, AMER SOC HEMATOLOGY, New Orleans, LA, presented at 55th Annual Meeting of the American-Society-of-Hematology, New Orleans, LA, 07 December 2013 - 10 December 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331385004173&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2013
Lemech C; Fontela A; Arkenau H; Chin M; Li S; Liauw WS; Thomas D; De Souza P, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at ASCO Annual Meeting, Chicago, USA, 01 June 2012 - 05 June 2012, http://meeting.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2Fe13585&allch=&submit=Go#abstr-1
2012
Soria J-C; Gan HK; Arkenau H-T; Blagden SP; Plummer R; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Brown J; Peddareddigari VGR; Gibson D; Murray SC; Nebot N; Mazumdar J; Fleming RA; Millward M, 2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 01 June 2012 - 06 June 2012, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2012
Lemech CR; Cosman R; Lee C; Friedlander M; Lewis C; Lynch J; Thomas D; Clingan P; Glasgow A, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf
2010
Conference Posters
add
Baird RD; Cresti N; Beddowes E; Saggese M; Flynn M; Garcia Corbacho J; Gao F; Lemech CR; Donaldson K; Posner J; Kawabat I; Forster M; Arkenau HT; Plummer R; Jodrell D; Spicer J, 2013, 'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily pre-treated HER2-positive metastatic breast cancer', presented at San Antonio Breast Cancer Symposium, 10 December 2013 - 14 December 2013, http://www.abstracts2view.com/sabcs13/viewp.php?nu=P4-12-24
2013
Ganguli S; Spiliopoulou P; Benafif S; Flynn M; Lemech CR; Saggese M; Forster M; Kristeleit R; Arkenau HT; Meyer T, 2013, 'Clinical outcomes for patients in early phase clinical trials: the UCLH and Sarah Cannon Research UK experience', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B65.htm
2013
Dua D; Lemech CR; Newmark J; Saggese M; Spiliopoulou P; Ash N; Williams I; Hauser J; Lauigan M; Muzengi M; Arkenau HT, 2013, 'Patients' perceptions of research biopsies on early phase oncology trials', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013
2013
Lemech CR; Newmark J; Arkenau HT, 2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice - a multi-institutional multi-national survey', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B101.htm
2013
Liauw W; Lemech CR, 2010, 'Diffuse peritoneal adenomucinosis in a patient wiht familial adenomatous polyposis', Melbourne, Victoria, Australia, presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne, Victoria, Australia, 09 November 2010 - 11 November 2010
2010
Lemech CR; Friedlander M, 2009, 'Clear cell cancer of the ovary: from resistance to response', Canberra Australia, presented at MOGA Annual Scientific Meeting, Canberra Australia, 12 August 2009 - 14 August 2009, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2009.01218.x/pdf
2009
Book Chapters
add
Lemech CR; Kristeleit R; Arkenau HT, 2011, 'Novel Oncology Drug Development Strategies in the Era of Personalised Medicine', in Kapetanovic IM (ed.), Drug Discovery and Development - Present and Future, INTECH EUROPE, pp. 43 - 68, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385879400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2011